To delineate aggressive RBness cancers independent of the bona fide RB1 defects (patients with low Rb or pRb, RB1 MTs, and/or deep deletions), we assessed the outcome of the RBNSig-high group’s patients with RBness (n = 328) independently. The gene discussed is RB1; the disease is cancer.